Prof. Rick Haas has been trained as a radiation-oncologist in the Netherlands Cancer Institute (NKI-AvL) from 1992 until 1997, where he remained as a staff member ever since. Between 2002 and 2015 he was responsible for the training of radiotherapy residents at the NKI-AvL.

He has the privilege of also occupying a research position at the Department of Radiotherapy at the LUMC since January 2017 where he was appointed as Professor in 2020. The title of his Chair is “Radiotherapy, with a focus on bone and soft tissue sarcomas”.

Although he is an all-round radiation-oncologist, his focus lies on soft tissue sarcomas (STS) and lymphomas. In 2006, he defended his PhD thesis, entitled “Low dose radiotherapy in indolent lymphomas, enough is enough”, prior to which he was the principal investigator (PI) of the phase II N97HOR and phase III HOVON 47 / EORTC 20013 trials.

Currently, his research projects focus on STS. He was the PI of several Phase I, II and III trials. In his preclinical in vitro studies, he investigated the RT fractionation sensitivity of STS cell lines, by means of which he created the “SCOPES” randomized clinical trial (NCT04425967).

Rick Haas served as CTOS President in the year 2021. Rick is married and he is the father of 3 children and a grandfather to 1 grandchild.